Vigil Neuroscience extends projected cash runway into second half of 2025

Vigil Neuroscience provided a 2023 year-in-review and outlined key milestones anticipated in 2024. The company also today announced that it has extended its projected cash runway into the second half of 2025. Based on the totality of the data reported in 2023 from the ILLUMINATE and IGNITE studies, the company plans to engage with the FDA in the first half of 2024 regarding a potential accelerated development pathway for iluzanebart in ALSP. The company has extended its projected cash runway into the second half of 2025 by focusing its financial resources on current business priorities, including its iluzanebart and VG-3927 clinical development programs. The company’s reallocation of capital is not expected to have any impact on employee headcount or anticipated development milestones. Vigil is on track to report interim data from the ongoing Phase 1 clinical trial of VG-3927 in healthy volunteers in mid-2024. The company expects to report Phase 2 results from its IGNITE clinical trial evaluating iluzanebart in ALSP from all patients at six months at both 20 mg/kg and 40 mg/kg doses in the third quarter of 2024.